Medical Journal Abstracts

Overview

Medical Journal Abstracts

The medical journal abstracts section provides healthcare professionals with access to key journal abstracts. Bringing together articles from a full range of sources, this resource aims to provide doctors with a starting point for their journal research.

The regularly updated journals can be sorted by disease/condition, source name and the date of publication. Alternatively they can be accessed within the relevant epgonline.org disease topic areas, via the collapsible menu at the top of each page of the epgonline.org website.

 

Latest Medical Journal Abstracts

Impact of eculizumab treatment on paroxysmal nocturnal hemoglobinuria: a treatment versus no-treatment study.

-4 days ago -  Impact of eculizumab treatment on paroxysmal nocturnal hemoglobinuria: a treatment versus no-treatment study.

Intravascular hemolysis in Paroxysmal nocturnal hemoglobinuria (PNH) can effectively be controlled with eculizumab, a humanized monoclonal antibody that binds complement protein C5. We report here a ...

Imatinib: a breakthrough of targeted therapy in cancer.

8 days ago -  Imatinib: a breakthrough of targeted therapy in cancer.

Deregulated protein tyrosine kinase activity is central to the pathogenesis of human cancers. Targeted therapy in the form of selective tyrosine kinase inhibitors (TKIs) has transformed the approach ...

Indacaterol–Glycopyrronium versus Salmeterol–Fluticasone for COPD

Sun 15 May 2016 -  Indacaterol–Glycopyrronium versus Salmeterol–Fluticasone for COPD

Background: Most guidelines recommend either a long-acting beta-agonist (LABA) plus an inhaled glucocorticoid or a long-acting muscarinic antagonist (LAMA) as the firstchoice treatment for patients ...

Real-world glycemic, blood pressure, and weight control in patients with type 2 diabetes mellitus treated with canagliflozin-an electronic health-record-based study.

Wed 11 May 2016 -  Real-world glycemic, blood pressure, and weight control in patients with type 2 diabetes mellitus treated with canagliflozin-an electronic health-record-based study.

Background: Canagliflozin (CANA) has been shown to improve HbA1c, blood pressure (BP), and weight in patients with type 2 diabetes mellitus (T2DM) in clinical trials. This study describes HbA1c, BP, ...

In vivo imaging of eribulin-induced reoxygenation in advanced breast cancer patients: a comparison to bevacizumab.

Tue 03 May 2016 -  In vivo imaging of eribulin-induced reoxygenation in advanced breast cancer patients: a comparison to bevacizumab.

Background: Eribulin mesylate (eribulin) is a first-in-class halichondrin B-based microtubule dynamics inhibitor. To compare the anti-angiogenic activity of eribulin to that of bevacizumab, we ...

Sustained efficacy of insulin pump therapy compared with multiple daily injections in type 2 diabetes: 12-month data from the OpT2mise randomized trial.

Sun 01 May 2016 -  Sustained efficacy of insulin pump therapy compared with multiple daily injections in type 2 diabetes: 12-month data from the OpT2mise randomized trial.

Aims: To compare insulin pump therapy and multiple daily injections (MDI) in patients with type 2 diabetes receiving basal and prandial insulin analogues. Methods: After a 2-month ...

Five-Year Outcomes with Anti–Vascular Endothelial Growth Factor Treatment of Neovascular Age-Related Macular Degeneration

Sun 01 May 2016 -  Five-Year Outcomes with Anti–Vascular Endothelial Growth Factor Treatment of Neovascular Age-Related Macular Degeneration

Purpose: To describe outcomes 5 years after initiating treatment with bevacizumab or ranibizumab for neovascular age-related macular degeneration (AMD). Design: Cohort study. Participants: ...

Elafibranor, an Agonist of the Peroxisome Proliferator-Activated Receptor-α and -δ, Induces Resolution of Nonalcoholic Steatohepatitis Without Fibrosis Worsening.

Sun 01 May 2016 -  Elafibranor, an Agonist of the Peroxisome Proliferator-Activated Receptor-α and -δ, Induces Resolution of Nonalcoholic Steatohepatitis Without Fibrosis Worsening.

Background & Aims Elafibranor is an agonist of the peroxisome proliferator−activated receptor-α and peroxisome proliferator−activated receptor-δ. Elafibranor improves ...

The role of vedolizumab in patients with moderate-to-severe Crohn's disease and ulcerative colitis.

Sun 01 May 2016 -  The role of vedolizumab in patients with moderate-to-severe Crohn's disease and ulcerative colitis.

Vedolizumab, an α4β7-integrin antagonist, is the first gut-selective monoclonal antibody that has been approved for the treatment of moderate-to-severe ulcerative colitis and Crohn's ...

Dapagliflozin in the treatment of patients with type 2 diabetes presenting with high baseline A1C.

Sun 01 May 2016 -  Dapagliflozin in the treatment of patients with type 2 diabetes presenting with high baseline A1C.

Objectives: To evaluate the efficacy and safety of dapagliflozin 5 and 10 mg/d versus placebo in patients with type 2 diabetes and high baseline A1C defined as A1C ≥ 9% or ≥ 10%. Methods: A ...

Journals by Disease Topic

Browse medical journal abstracts by selecting from disease topic. Alternatively click the “View All” button to access our entire database to filter Medical Journal Abstracts by year.

Browse Medical Journal Abstracts by Year

Browse medical journal abstracts by year, then further select by month for the latest medical abstracts and articles available.

Back to top